In the Name of Transparency: Organizing European pharmaceutical markets through struggles over transparency devices

Abstract

The controversies surrounding the heavily redacted contracts between the European Commission and COVID-19 vaccine producers have highlighted ‘transparency’ as a hotly debated concept in the pharmaceutical market. We combine research on transparency with literature on the organization of markets to investigate how such struggles over competing visions of transparency end up shaping markets and their politics. Focusing on the case of the European pharmaceutical market, we demonstrate how market transparency was implemented through devices that enacted specific visions of transparency and produced distinct market organizations over time: transparency for states (until about 1990), transparency for corporations (ca. 1990 to 2010), and transparency for state coalitions (since 2010). We discuss how the specific instrumentations and materializations of such visions of transparency play a crucial role in market politics. This debate also highlights why engaging in controversies over transparency has become increasingly important for those contesting the market status quo – in pharmaceutical markets and beyond.

Choreographing for public value in digital health?

“…Internet searches yielded extensive grey literature (e.g., Tech Republic, Tech Central, TechHive, TechCrunch, FastCompany, Mashable, Digital Health, MedCity News, mHealth Intelligence, Fortune, Forbes, The Wall Street Journal or Bloomberg) – 352 documents – over a 10 year-period of researching digital health. While we focused on the choreographing at EU level, we also ‘zoomed’ into how this choreographing is interpreted and implemented at a national level (Geiger and Bourgeron, 2023). We chose Ireland for this empirical deep dive because we had developed substantial expertise through prior research in this EU nation.…”